Sanofi is making an initial $30 million investment in MeiraGTx to gain a first peek at data from the biotech’s riboswitch platform, all for a chance to someday brew up some new deals. MeiraGTx sold 4 million ordinary shares for $7.50 apiece, providing access to a first look at data from programs in immunology and inflammation, central nervous disorders and GLP-1 and other gut peptides for metabolic diseases. Source: Fierce Biotech 31/10/2023